Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
17 avr. 2018 13h01 HE
|
Mersana Therapeutics, Inc.
Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor CAMBRIDGE, Mass.,...
Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018
09 avr. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
28 mars 2018 07h30 HE
|
Mersana Therapeutics, Inc.
Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2 Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting...
Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
19 mars 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Appoints David A. Spellman as Chief Financial Officer
12 mars 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
07 févr. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals
08 janv. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
20 déc. 2017 16h01 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Added to NASDAQ Biotechnology Index
15 déc. 2017 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors
12 déc. 2017 08h00 HE
|
Mersana Therapeutics, Inc.
Trial to Study Patients in Ovarian, NSCLC and Other Cancers XMT-1536 is Second Dolaflexin Antibody Drug Conjugate to Enter Clinical Trials CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) --...